Ninety-two percent of all patients presented with poor risk in the tumor extent category (T), 40% of patients had a CD4 count less than 150 cells/microliter, categorizing them as poor risk with respect to immune system function (I), and 73% had poor risk with respect to presence of systemic illness (S). The gene discussed is CD4; the disease is neoplasm.